BTK inhibitors have transformed B-cell malignancy treatment, with distinct resistance mechanisms linked to specific inhibitors. Covalent inhibitors often lead to BTK C481 mutations, while non-covalent ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results